Immunocore appoints CMO
This article was originally published in Scrip
Executive Summary
Immunocore, a biotechnology company developing drugs to treat cancer, viral infections and autoimmune disease, has named Christina Coughlin chief medical officer. Dr Coughlin will be responsible for providing medical and regulatory leadership to the preclinical and clinical programs for the company. Most recently, Dr Coughlin was leading two early development program at Novartis in checkpoint inhibition and PI3'kinase inhibition. Prior to this she was international project team leader at Morphotek, a monoclonal antibody company acquired by Eisai in 2007.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.